Journal of Biotechnology & Biomaterials
Open Access

Research Article

Safety of Mesenchymal Stem Cells Therapy in Patients with Inflammatory Bowel Diseases 5 Year Follow-Up

¹Central Research Institute of Gastroenterology, Department of Treatment Inflammatory Bowel Diseases, Russia

²Central Research Institute of Gastroenterology, Department of Intestinal Pathology, Russia

³Central Research Institute of Gastroenterology, Department of Experimental Radiotherapy, Russia

⁴Candidate of Science, Scientist Researcher, Russia

Corresponding Author:

Knyazev Oleg Vladimirovich
Central Research Institute of Gastroenterology
Doctor of science
Head of Department of Treatment Inflammatory Bowel Diseases, Russia
E-mail: oleg7@bk.ru

Kagramanova Anna Valeryevna
Central Research Institute of Gastroenterology
Candidate of Science, Scientist Researcher, Russia
Tel: +79260804444
E-mail: kagramanova@me.com

Received date:: May 05, 2015; Accepted date:: August 13, 2015; Published date:: August 20, 2015

Citation: Knyazev OV, Parfenov AI, Konoplaynnikov AG, Kagramanova AV, Churikova Alevtina Alekseevna, et al. (2015) Safety of Mesenchymal Stem Cells Therapy in Patients with Inflammatory Bowel Diseases – 5 Year Follow-Up. J Biotechnol Biomater 5:192. doi:10.4172/2155-952X.1000192

Copyright: © 2015 Vladimirovich KO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Aim: To compare safety profile of therapy in patients with ulcerative colitis (UC) and Crohn disease (СD), receiving anti-inflammatory therapy, using bone marrow-derived mesenchymal stromal cells (MSC) and standard therapy with 5-aminosalicylic acid (5-ASA), glucocorticosteroids (GCS) and immunosuppressive agents (IS).

Materials and methods: Adverse events were analyzed in 103 patients with inflammatory bowel disease (IBD) after administration MSCs (56 patients UC and 47 patients CD). The findings were compared with data obtained in 208 patients with UC and CD, receiving standard anti-inflammatory therapy. All analyzed patients were similar in demographic characteristics, the duration of disease, the extent of disease, course of disease, phenotype and degree of disease. The analyzed groups did not include patients, treated with anti-TNF therapy. The safety of therapy was evaluated by presence of complications, developed during follow-up period.

Results: We conducted analysis of side effects in 103 IBD patients, treated with mesenchymal stem cells, comparing with 208 UC and CD patients, treated with standard anti-inflammatory therapy and finally we did not reveal any differences in developing acute post-transfusional toxicity, infectious complications, exacerbation of chronic inflammatory diseases, serious infectious complications, malignancy and death in UC and CD patients, besides transitive febrile.

Conclusion: Results of our study show that innovative method of cell therapy is safe in clinical practice.

Keywords